Skip to main content
. 2016 Apr 18;9:2287–2295. doi: 10.2147/OTT.S97583

Figure 4.

Figure 4

In the NCT group, patients who received both trastuzumab and chemotherapy (trastuzumab+ group) exhibited a longer DFS than those who received chemotherapy alone (trastuzumab− group) (P=0.049) (95% CI: 0.213–0.998; HR: 0.461).

Abbreviations: CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; NCT, neoadjuvant chemotherapy.